Belinostat: all 50 studies that test it

Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and ToxicityRecruitingNCT06406465Phase 2
• Testing the Combination of Belinostat and SGI-110 (Guadecitabine) or ASTX727 for the Treatment of Unresectable and Metastatic Conventional ChondrosarcomaActive, not recruitingNCT04340843Phase 2Results posted
• Ribociclib&Belinostat In Patients w Metastatic Triple Neg Breast Cancer & Recurrent Ovarian Cancer w Response Prediction By GenomicsTerminatedNCT04315233Phase 1Results posted
• Pevonedistat and Belinostat in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic SyndromeTerminatedNCT03772925Phase 1Results posted
• Belinostat Therapy With Zidovudine for Adult T-Cell Leukemia-LymphomaCompletedNCT02737046Phase 2Results posted
• Belinostat and Yttrium Y 90 Ibritumomab Tiuxetan in Patients W/Relapsed Aggressive B-Cell NHLCompletedNCT01686165Phase 2Results posted
• Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic DysfunctionCompletedNCT01273155Phase 1Results posted
• Belinostat and Carboplatin in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer That Did Not Respond to Carboplatin or CisplatinCompletedNCT00993616Phase 2Results posted
• A Phase I/II Clinical Trial of PXD101 in Combination With Doxorubicin in Patients With Soft Tissue SarcomasCompletedNCT00878800Phase 1/2Results posted
• Trial of PXD101 (Belinostat) in Combination With Idarubicin to Treat AML Not Suitable for Standard Intensive TherapyCompletedNCT00878722Phase 1/2Results posted
• Belinostat, Carboplatin and Paclitaxel (BelCaP) Compared to Carboplatin and Paclitaxel in Patients With Cancer of Unknown PrimaryCompletedNCT00873119Phase 2Results posted
• Belinostat in Relapsed or Refractory Peripheral T-Cell LymphomaCompletedNCT00865969Phase 2Results posted
• Belinostat (PXD101) to Treat Tumors of the Thymus at an Advanced StageCompletedNCT00589290Phase 2Results posted
• A Study of Belinostat + Carboplatin or Paclitaxel or Both in Patients With Ovarian Cancer in Need of Relapse TreatmentCompletedNCT00421889Phase 1/2Results posted
• PXD101 as Second-Line Therapy in Treating Patients With Malignant Mesothelioma of the Chest That Cannot Be Removed By SurgeryCompletedNCT00365053Phase 2Results posted
• Belinostat in Treating Patients With Myelodysplastic SyndromesCompletedNCT00357162Phase 2Results posted
• PXD101 in Treating Patients With Acute Myeloid LeukemiaCompletedNCT00357032Phase 2Results posted
• Belinostat in Treating Patients With Liver Cancer That Cannot Be Removed By SurgeryCompletedNCT00321594Phase 1/2Results posted
• PXD101 in Treating Patients With Relapsed or Refractory Aggressive B-Cell Non-Hodgkin's LymphomaCompletedNCT00303953Phase 2Results posted
• Belinostat in Treating Patients With Advanced Ovarian Epithelial Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer or Ovarian Low Malignant Potential TumorsCompletedNCT00301756Phase 2Results posted
• A Phase II Clinical Trial of PXD101 in Patients With Recurrent or Refractory Cutaneous and Peripheral T-Cell LymphomasTerminatedNCT00274651Phase 2Results posted
• To Evaluate Efficacy of Belinostat or Pralatrexate in Combination Against CHOP Alone in PTCLActive, not recruitingNCT06072131Phase 3
• Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted TreatmentActive, not recruitingNCT05627245Phase 1
• Binimetinib Plus Belinostat for Subjects With Metastatic Uveal MelanomaActive, not recruitingNCT05170334Phase 2
• Tremelimumab + Durvalumab(MEDI4736)+ Belinostat in Urothelial CarcinomaCompletedNCT05154994Phase 1
• Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian CancerCompletedNCT04703920Phase 1
• Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell LymphomasWithdrawnNCT02875002Phase 1
• Belinostat Combined With Azacitidine/Gemcitabine/Busulfan/Melphalan With Autologous Stem-Cell Transplantation in Refractory or Relapsed LymphomaWithdrawnNCT02701673Phase 1/2
• Establish the PK of Belinostat in Patients With Wild-type, Heterozygous, and Homozygous UGT1A1*28 GenotypesCompletedNCT02680795Phase 1
• To Evaluate Safety and Pharmacokinetics of Belinostat in Patients Who Have Mild, Moderate and Severe Renal Impairment.TerminatedNCT02679131Phase 1
• A Phase Ib Study of Belinostat With RDHAP Chemotherapy (Dexamethasone, Cytarabine, Cisplatinum) in Adults With Relapsed or Refractory Diffuse Large B-cell LymphomaWithdrawnNCT02532192Phase 1
• Phase I Trial of AZD1775 and Belinostat in Treating Patients With Relapsed or Refractory Myeloid Malignancies or Untreated Acute Myeloid LeukemiaTerminatedNCT02381548Phase 1
• Carfilzomib Plus Belinostat in Relapsed/Refractory NHLCompletedNCT02142530Phase 1
• MRSI to Predict Response to RT/TMZ ± Belinostat in GBMActive, not recruitingNCT02137759Phase 2
• Phase 1 Dose Finding Study of Belinostat for Treatment of Patients With Peripheral T-cell Lymphoma (PTCL)CompletedNCT01839097Phase 1
• Phase I Mass Balance, PK and Safety Study of 14C-Labeled Belinostat in Patients With Advanced CancerCompletedNCT01583777Phase 1
• A Study of Belinostat in Combination With Warfarin in Patients With Solid Tumors or Hematological MalignanciesCompletedNCT01317927Phase 1
• MTD Study PXD-101 in Combination With Paclitaxel + Carboplatin in Chemotherapy-Naive Patients With Stage IV NSCLCCompletedNCT01310244Phase 1/2
• A Trial of Belinostat in Combination With Erlotinib in Patients With Non-small Cell Lung CancerTerminatedNCT01188707Phase 1/2
• Safety and Efficacy of Belinostat When Used With Standard of Care Chemotherapy for Untreated Non-small Cell Lung CancerTerminatedNCT01090830Phase 1/2
• Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic SyndromeCompletedNCT01075425Phase 1
• A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced CancersCompletedNCT00926640Phase 1
• A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple MyelomaTerminatedNCT00431340Phase 2
• Study of PXD101 Alone and in Combination With 5-Fluorouracil (5-FU) in Patients With Advanced Solid TumorsCompletedNCT00413322Phase 1
• Study of Oral PXD101 in Patients With Advanced Solid Tumors or LymphomaCompletedNCT00413075Phase 1
• PXD101 and 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Metastatic or Unresectable Solid Tumors or LymphomaTerminatedNCT00354185Phase 1
• Belinostat and Azacitidine in Treating Patients With Advanced Hematologic Cancers or Other DiseasesCompletedNCT00351975Phase 1
• PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or LymphomasCompletedNCT00348985Phase 1
• Belinostat and Isotretinoin in Treating Patients With Solid Tumors That Are Metastatic or That Cannot Be Removed by SurgeryCompletedNCT00334789Phase 1
• Clinical Trial of PXD101 in Patients With Advanced Multiple MyelomaCompletedNCT00131261Phase 2

← Belinostat overview